Bayer said it will continue to sell Essure in the US and the US Food and Drug Administration (FDA) will continue to monitor the device, which has been on the market for approximately 10 years. The device is a permanent birth form of birth control that involves two nickel-titanium coils placed inside the fallopian tubes to encourage the growth of scar tissue that eventually blocks the tubes to prevent pregnancy.
In 2016, the FDA added its most stringent warning, a boxed warning, to the product, to alert doctors and patients to problems reported with the implant. This came in addition to the pre-existing warning of pelvic pain and bleeding immediately after the implant procedure.
READ MORE Essure LEGAL NEWS
According to the statement issued by Bayer and reported by CBS News, "Essure's safety and effectiveness remain supported by more than ten years of scientific research and real-life clinical experience." It cites "an environment unfavorable to its prescription" as the cause of "a continuous decline in demand" for the last several months.